YGT Investment

YGT (Young Gene Technology) is a clinical-stage biotechnology company specializing in the development of innovative gene therapies for ophthalmic and rare diseases. The company leverages its proprietary Adeno-Associated Virus (AAV) vector platform to design and manufacture high-potency genetic medicines aimed at restoring vision. Its lead program, YGT-001, is an AAV-based gene therapy targeting RPE65-mediated inherited retinal dystrophies, such as Leber Congenital Amaurosis. Headquartered in Beijing, YGT has established comprehensive capabilities spanning drug discovery, clinical development, and GMP manufacturing. The company is backed by prominent investors including 5Y Capital and IDG Capital, and it continues to expand its pipeline to address various forms of blindness and other genetic disorders.